Heart & Vascular

Philips Stellarex Clinical Summary: Illuminate Pivotal Randomized Trial

Case study: Severely Calcified SFA Stenosis:

  • Stellarex is the only DCB reported to have durable patency at 2 years in severely calcified lesions

  • Stellarex demonstrates a robust treatment effect over PTA in severely calcified lesions

  • 82% of the severely calcified segments were greater than 50% of the total lesion length

 

 

 

 

 

D045227-00